Climb Bio reports Q1 2026 cash of $146.3M; $110M private placement closed April 29

Climb Bio, Inc.

R&D expense $9.4M vs $17.3M YoY (incl. $9M CLYM116 upfront in prior year); G&A $5.8M.
Cash, equivalents, and marketable securities $146.3M as of March 31; expects to fund ops into 2028 excluding $110M placement.
Budoprutug SC formulation showed robust B-cell depletion similar to IV; Phase 2 pMN trial granted FDA Fast Track Designation.
Initial budoprutug ITP data (low-dose B-cell and platelet) expected June 2026; pMN data Q4 2026.
CLYM116 nonhuman primate-to-human PK/PD modeling and initial safety data to be presented at ERA June 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.